Clinical trial · Interventional
PCI for Patients With ES-SCLC After RCT:a Prospective Randomized Study
A Prospective Randomized Controlled Study for Prophylactic Cranial Irradiation After Chemotherapy and Thoracic Radiation Therapy in Patients With Extensive-stage Small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
prophylactic cranial irradiation （PCI）was verified to decrease the brain metastases rates and improve the overall survival（OS）for patients with limited stage small cell lung cancer.We hypothesis that patients with extensive-stage small cell lung cancer after chemotherapy and thoracic radiation can also benefit from PCI.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small-cell Lung Cancer | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| prophylactic cranial irradiation | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- PCI group
- description
- patients received 4-6 circles of chemotherapy of EP or EC，and patients with complete remission or partial remission (more than 1 site) after chemotherapy，patients received thoracic radiotherapy and prophylactic cranial irradiation。
- interventionNames
- Radiation: prophylactic cranial irradiation
- type
- OTHER
- label
- control group
- description
- patients received 4-6 circles of chemotherapy of EP or EC，and patients with complete remission or partial remission (more than 1 site) after chemotherapy，patients received thoracic radiotherapy。
- interventionNames
- Radiation: prophylactic cranial irradiation
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * 18-65 years old,KPS≥70 * Pathological or cytological diagnosis of stage IV small cell lung cancer (by using AJCC 7th edition staging criteria); * 1-3 extra-cranial metastatic organs before chemotherapy; 4-6 cycles of CE or EP ； * CR or PR after chemotherapy； * no grade ≥II side effects; * the estimated overall survival time ≥ 3 months; * no serious medical disease or major organ dysfunction. Exclusion Criteria: * Patients with brain or nervous system metastases; * Presence of high grade radiation comorbidities; * Patients who are pregnant or lactating
References
Publications (0)
Data not yet available